605186.SHG Shanghai General Healthy Information and Technology Co. Ltd.
- Market cap
- CNY 2.86B
- P/E
- 100.1x
- P/B
- 2.49x
- ROE
- 1.3%
- Dividend yield
- 0.14%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 605186.SHG undervalued?
Graham numberThe Graham number of Shanghai General Healthy Information and Technology Co. Ltd. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai General Healthy Information and Technology Co. Ltd. fundamental analysis
No fundamental analysis for Shanghai General Healthy Information and Technology Co. Ltd. yet.
Shanghai General Healthy Information and Technology Co. Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai General Healthy Information and Technology Co. Ltd.
Shanghai General Healthy Information and Technology Co., Ltd. provides pharmaceutical logistics automation, information technology, and intelligent and mobile medical solutions in China. It operates through four segments: Smart Pharmacy Project, Intelligent Static Compounding Center Project, Intelligent Drug and Consumable Management Project, and Logistics and Mobile Robot Project. The company's products include the Smart Pharmacy Project, an intelligent drug management syst…
Full company profileShanghai General Healthy Information and Technology Co. Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shanghai General Healthy Information and Technology Co. Ltd. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 205M | 233M | 256M | 300M | 287M | 490M | 322M | 308M | 318M | 345M | 370M |
| Gross Profit | 126M | 141M | 148M | 168M | 171M | 207M | 192M | 169M | 124M | 151M | 137M |
| Operating Income | 57.9M | 83.5M | 104M | 121M | 124M | 144M | 132M | 67.6M | 37.3M | 58.2M | 23.6M |
| EBITDA | 62.0M | 84.9M | 106M | 123M | 126M | 147M | 135M | 73.9M | 60.3M | 59.0M | 20.2M |
| Net Income | 17.6M | 55.4M | 74.6M | 91.9M | 95.7M | 118M | 116M | 60.0M | 32.5M | 30.8M | 14.2M |
| EPS | 8.07 | 0.54 | 0.73 | 0.90 | 0.94 | 0.86 | 0.85 | 0.44 | 0.24 | 0.23 | 0.10 |
| Balance Sheet | |||||||||||
| Total Assets | 257M | 263M | 355M | 482M | 997M | 1.13B | 1.20B | 1.32B | 1.47B | 1.50B | 1.57B |
| Total Liabilities | 97.0M | 85.0M | 99.8M | 131M | 120M | 154M | 116M | 179M | 305M | 313M | 360M |
| Shareholders' Equity | 117M | 121M | 196M | 288M | 813M | 902M | 1.00B | 1.05B | 1.07B | 1.10B | 1.11B |
| Cash & Short-term Investments | 94.2M | 102M | 134M | 149M | 560M | 469M | 366M | 268M | 124M | 186M | 70.6M |
| Total Debt | - | - | 2.02M | 42.6M | 11.9M | 4.30M | 6.55M | 50.0M | 126M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 58.2M | 57.0M | 67.9M | 76.0M | 71.8M | 53.8M | -37.3M | -35.4M | 17.7M | 96.7M | - |
| Capital Expenditure | 4.98M | 916K | 23.7M | 96.6M | 60.9M | 81.4M | 66.7M | 37.1M | 137M | 24.5M | 11.0M |
| Free Cash Flow | 53.2M | 56.1M | 44.2M | -20.5M | 10.9M | -27.5M | -104M | -72.5M | -119M | 72.3M | -198M |
| Ratios | |||||||||||
| ROE | 15.0% | 45.8% | 38.1% | 32.0% | 11.8% | 13.0% | 11.5% | 5.7% | 3.0% | 2.8% | 1.3% |
| ROA | 6.9% | 21.0% | 21.0% | 19.1% | 9.6% | 10.4% | 9.6% | 4.6% | 2.2% | 2.1% | 0.9% |
| Net Profit Margin | 8.6% | 23.8% | 29.1% | 30.6% | 33.4% | 24.0% | 35.9% | 19.5% | 10.2% | 8.9% | 3.8% |
| Debt to Equity | - | - | 0.01x | 0.15x | 0.01x | 0.00x | 0.01x | 0.05x | 0.12x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shanghai General Healthy Information and Technology Co. Ltd. dividends
- Dividend yield
- 0.14%
- Forward dividend
- -
- Payout ratio
- 13.0%
- Ex-dividend date
- Aug 23, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 3.99M | 0.03 | 13.0% |
| 2024 | CNY 16.4M | 0.12 | 50.5% |
| 2023 | CNY 13.0M | 0.09 | 21.6% |
| 2022 | CNY 12.2M | 0.09 | 10.6% |
| 2021 | CNY 29.2M | 0.21 | 24.9% |
| 2020 | - | - | - |
| 2019 | CNY 9.86M | 0.10 | 10.7% |
| 2018 | 16.5M | 0.16 | 22.1% |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Shanghai General Healthy Information and Technology Co. Ltd.
- Insiders 50.82%
- Institutions 2.47%
- Public & others 46.71%
- Shares outstanding 136M
- Free float 84.6M
Shanghai General Healthy Information and Technology Co. Ltd. company profile
- Company name
- Shanghai General Healthy Information and Technology Co. Ltd.
- Ticker
- 605186.SHG
- ISIN
- CNE100006BJ1
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 337
- Fiscal year end
- December
- Address
- No. 518, Zhongchen Road, Shanghai, China, 201613
- Phone
- 86 21 5786 0888
- Website
- g-healthy.com
About Shanghai General Healthy Information and Technology Co. Ltd.
Shanghai General Healthy Information and Technology Co., Ltd. provides pharmaceutical logistics automation, information technology, and intelligent and mobile medical solutions in China. It operates through four segments: Smart Pharmacy Project, Intelligent Static Compounding Center Project, Intelligent Drug and Consumable Management Project, and Logistics and Mobile Robot Project. The company's products include the Smart Pharmacy Project, an intelligent drug management system that combines software and hardware; intelligent static distribution center project, an intelligent intravenous drug configuration and management system; and Intelligent Drug Consumables Management Project, a management system for drug consumables, including poisonous hemp drugs and high-value medical consumables. Shanghai General Healthy Information and Technology Co., Ltd. was founded in 2014 and is based in Shanghai, China.
Shanghai General Healthy Information and Technology Co. Ltd. management
9- Mr. Jianwei DaiChairman of the Board & GM · born 1962
- Mr. Hong QiuDeputy GM, CFO, Secretary of the Board of Directors & Director · born 1980
- Mr. Gang ChengExecutive VP & Director · born 1973
- Mr. Ling ZhaoDeputy GM & Director · born 1977
- Mr. Jianfeng LuoDeputy General Manager · born 1976
- Mr. Junhua ZhangDeputy General Manager · born 1984
- Mr. Weiyong GongDeputy General Manager · born 1983
- Ying ZhuAccounting Supervisor
- Mr. Shaodeng WangSales Director · born 1987